Role of Magnesium Supplement on Hyperlipidemia and L-CAT Level in Patient on Atorvastatin Therapy.
Loading...
Date
2014-06
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Aim: This study aimed to evaluate the effect of magnesium supplement to atorvastatin on
hyperlipidemic patients and to elucidate the possible ability of oral magnesium
supplement to counteract or delay statins induced myalgia.
Study Design: Forty hyperlipidemic male and female patients were randomly divided into
two groups: group one consisted of twenty patients, who received atorvastatin 10 mg
once daily for 6 weeks then 20 mg once daily for another 6 weeks; group two consisted of
twenty patients, who received the same dose of atorvastatin plus once daily oral low dose
magnesium sulfate trihydrate 419.5 mg equivalent to 50 mg of magnesium.
Place and Duration of Study: The Laboratory of Pharmaceutical Research Center of
Faculty of Pharmacy, Tanta University, Egypt, between July to December 2013.
Methodology: Two samples of venous blood (2 ml + 8 ml =10 ml total), were collected
from all individuals, and were drawn from the antecubital vein before, 1.5 and 3 months
after treatment. Sera and plasma were separated immediately for biochemical analyses of
lecithin cholesterol acyltransferase (L-CAT) (ELISA), creatine kinase (CK), serum Ca+,
Mg++, Na+, K+, lipid profile and aspartate transaminase (AST) (colorimetrically), and serum
creatinine (S.Cr) spectrophotometrically.
Results: The statistical analysis revealed that, 3 months after treatment, both groups
showed significant amelioration in lipid profiles and significant elevation in L-CAT level regarding to baseline data obtained before initiation of treatment. In addition, the patients
received atorvastatin plus magnesium supplement showed significantly higher levels of
serum magnesium, plasma L-CAT and HDL-cholesterol concentrations and significantly
lower total cholesterol, LDL-cholesterol and triglycerides concentrations with non
significant lower CK level as compared to the patients group received atorvastatin solely.
Conclusion: Mg++ supplement to atorvastatin improve all lipid profile and provide better
control on dyslipidemia than atorvastatin alone. However, Mg++ supplement to atorvastatin
doesn’t prevent elevation in CK; it may delay and provide some protection against statin
induced myopathy that in turn may increase patient compliance.
Description
Keywords
Hyperlipidemia, atorvastatin, magnesium, lipid profiles, L-CAT
Citation
El-Haggar Sahar M, Mostafa Tarek M. Role of Magnesium Supplement on Hyperlipidemia and L-CAT Level in Patient on Atorvastatin Therapy. British Journal of Pharmaceutical Research. 2014 June; 4(12): 1521-1534.